Drug Profile
Efavirenz/lamivudine/tenofovir disoproxil fumarate - Cipla
Alternative Names: Efavirenz 600mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg - Cipla; Efavirenz/tenofovir disoproxil fumarate/lamivudine - Cipla; Lamivudine/efavirenz/tenofovir disoproxil fumarate - Cipla; Lamivudine/tenofovir disoproxil fumarate/efavirenz - Cipla; Tenofovir disoproxil fumarate/efavirenz/lamivudine - Cipla; TriodayLatest Information Update: 27 Nov 2018
Price :
$50
*
At a glance
- Originator Cipla
- Class Alkynes; Antiretrovirals; Benzoxazines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 27 Nov 2018 Efavirenz/lamivudine/Tenofovir disoproxil fumarate is not yet avaliable in USA for HIV-1 infections (Cipla website, November 2018)